share_log

Insiders Of Gossamer Bio Are Up 38% On Their US$1.27m Purchase

Insiders Of Gossamer Bio Are Up 38% On Their US$1.27m Purchase

Gossamer Bio的內部人士在127萬美元的收購中上漲了38%
Simply Wall St ·  03/01 05:32

Gossamer Bio, Inc. (NASDAQ:GOSS) insiders who bought shares over the past year were rewarded handsomely last week. The stock rose 22%, resulting in a US$56m rise in the company's market capitalisation, translating to a gain of 38% on their initial investment. As a result, the stock they originally bought for US$1.27m is now worth US$1.74m.

在過去一年中購買股票的Gossamer Bio, Inc.(納斯達克股票代碼:GOSS)內部人士上週獲得了豐厚的回報。該股上漲了22%,導致該公司的市值增長了5600萬美元,這意味着他們的初始投資收益了38%。結果,他們最初以127萬美元的價格購買的股票現在價值174萬美元。

While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

儘管在長期投資中,內幕交易並不是最重要的事情,但邏輯要求你應該注意內部人士是在買入還是賣出股票。

The Last 12 Months Of Insider Transactions At Gossamer Bio

Gossamer Bio 過去 12 個月的內幕交易

Over the last year, we can see that the biggest insider purchase was by Co-Founder Faheem Hasnain for US$1.0m worth of shares, at about US$1.20 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$1.41. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

在過去的一年中,我們可以看到,最大的內幕收購是聯合創始人Faheem Hasnain以每股約1.20美元的價格收購了價值100萬美元的股票。儘管我們希望看到內幕買盤,但我們注意到此次大宗收購遠低於最近的1.41美元價格。儘管這確實表明內部人士認爲該股在較低的價格下被低估,但這筆交易並沒有告訴我們他們對當前價格的看法。

Happily, we note that in the last year insiders paid US$1.3m for 1.23m shares. But they sold 22.97k shares for US$26k. In the last twelve months there was more buying than selling by Gossamer Bio insiders. Their average price was about US$1.03. It is certainly positive to see that insiders have invested their own money in the company. However, you should keep in mind that they bought when the share price was meaningfully below today's levels. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

令人高興的是,我們注意到,去年內部人士支付了130萬美元購買了123萬股股票。但他們以2.6萬美元的價格出售了22.97萬股股票。在過去的十二個月中,Gossamer Bio內部人士的買入量多於賣出量。他們的平均價格約爲1.03美元。看到內部人士將自己的資金投資於該公司,這無疑是積極的。但是,您應該記住,他們在股價明顯低於今天的水平時買入。您可以看到下圖所示的去年的內幕交易(公司和個人)。如果你想確切地知道誰賣了、賣了多少以及何時出售,只需點擊下圖!

insider-trading-volume
NasdaqGS:GOSS Insider Trading Volume March 1st 2024
納斯達克GS: GOSS 內幕交易量 2024 年 3 月 1 日

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

內部人士總是會買入很多股票。因此,如果這適合你的風格,你可以逐一查看每隻股票,也可以看看這份免費的公司名單。(提示:業內人士一直在購買它們)。

Insider Ownership

內部所有權

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Insiders own 3.0% of Gossamer Bio shares, worth about US$9.1m, according to our data. Whilst better than nothing, we're not overly impressed by these holdings.

測試公司領導者與其他股東之間一致性的另一種方法是查看他們擁有多少股份。我們通常希望看到相當高的內部所有權。根據我們的數據,內部人士擁有Gossamer Bio3.0%的股份,價值約910萬美元。雖然總比沒有好,但這些持股並沒有給我們留下太深的印象。

So What Does This Data Suggest About Gossamer Bio Insiders?

那麼這些數據對Gossamer Bio內部人士有什麼啓示呢?

The fact that there have been no Gossamer Bio insider transactions recently certainly doesn't bother us. But insiders have shown more of an appetite for the stock, over the last year. We'd like to see bigger individual holdings. However, we don't see anything to make us think Gossamer Bio insiders are doubting the company. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. For instance, we've identified 4 warning signs for Gossamer Bio (2 are a bit unpleasant) you should be aware of.

最近沒有Gossamer Bio的內幕交易這一事實肯定不會打擾我們。但是,在過去的一年中,內部人士對該股表現出了更大的興趣。我們希望看到更多的個人持股。但是,我們認爲沒有任何東西可以讓我們認爲Gossamer Bio內部人士對該公司表示懷疑。雖然我們喜歡了解內部人士的所有權和交易情況,但在做出任何投資決策之前,我們一定要考慮股票面臨的風險。例如,我們已經確定了你應該注意的Gossamer Bio的4個警告信號(其中2個有點不愉快)。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,來看看這份有趣的公司的免費清單吧。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論